

I



I a

in which:

A is $(C_1\text{-}C_4)$-alkylene;

S1 is a free electron pair or $(C_1\text{-}C_4)$-alkyl;

S2 is $(C_1\text{-}C_4)$-alkyl or H;

where, if S1 and S2 are alkyl, a group $-N^+(S1S2)-X^-$ results, wherein X^- corresponds to a pharmacologically acceptable anion or trifluoroacetate;

B is a saturated or unsaturated five-, six- or seven-membered carbon ring which may be mono- or, independently of one another, polysubstituted by oxo, hydroxyl, $(C_1\text{-}C_4)$-alkoxy and $(C_1\text{-}C_4)$-alkyl;

and

R1, R2, R3, R4 and R5

are, independently of one another, H, OH, F, Cl, Br, I, CN, NO_2, amidino, $-CO_2R(11)$, $-CONR(11)R(12)$, $-SO_rR(11)$, $-SO_sNR(11)\text{-}R(12)$, $(C_1\text{-}C_4)$-alkyl, $(C_1\text{-}C_4)$-alkoxy, $(C_1\text{-}C_4)$-alkoxy-$(C_1\text{-}C_4)$-alkyl, $(C_1\text{-}C_4)$-alkoxy-$(C_1\text{-}C_4)$-alkyloxy, hydroxy-$(C_1\text{-}C_4)$-alkyl, $(C_3\text{-}C_7)$-cycloalkoxy or phenyloxy,

where phenyl is unsubstituted or substituted by up to three substituents, which are independent of one another and are F, Cl, Br, or methoxy;

amino, $(C_1\text{-}C_4)$-alkylamino, di-$(C_1\text{-}C_4)$-alkylamino, amino-$(C_1\text{-}C_4)$-alkyl, di-$(C_1\text{-}C_4)$-alkylamino-$(C_1\text{-}C_4)$-alkyl, $(C_1\text{-}C_4)$-alkylamino-$(C_1\text{-}C_4)$-alkyl,

where some or all of the hydrogen atoms in the alkyl radicals may be substituted by fluorine;

R11 and R12

are, independently of one another, H or $(C_1\text{-}C_4)$-alkyl,

where some or all of the hydrogen atoms in the alkyl radicals may be substituted by fluorine;

r is 0, 1 or 2;

s is 1 or 2;

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

or

at least one of R1 and R2, R2 and R3, R3 and R4, and R4 and R5

together form one or more groups -O-$(CH_2)_n$-O-;

n is 1 or 2;

and

the radical or radicals R1, R2, R3, R4 and R5 which do not form said group or groups -O-$(CH_2)_n$-O-

is or are, independently of one another, H, OH, F, Cl, Br, I, CN, NO_2, amidino, $-CO_2R(11)$, -CONR(11)R(12), $-SO_rR(11)$, $-SO_sNR(11)$-R(12), $(C_1$-$C_4)$-alkyl, $(C_1$-$C_4)$-alkoxy, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkoxy, hydroxy-$(C_1$-$C_4)$-alkyl, amino, $(C_1$-$C_4)$-alkyl-amino, di-$(C_1$-$C_4)$-alkylamino, amino-$(C_1$-$C_4)$-alkyl, di-$(C_1$-$C_4)$-alkylamino-$(C_1$-$C_4)$-alkyl, $(C_1$-$C_4)$-alkylamino-$(C_1$-$C_4)$-alkyl,

where some or all of the hydrogen atoms in the alkyl radicals may be substituted by fluorine;

R11 and R12

are, independently of one another, H or $(C_1$-$C_4)$-alkyl,

where some or all of the hydrogen atoms in the alkyl radicals may be substituted by fluorine;

r is 0, 1 or 2;

s is 1 or 2;

except for benzyl(octahydro-4,7-methanoinden-5-yl)amine.

REMARKS

Claims 1-50 are pending in this application. Claims 7-34 and 38-50 are withdrawn from consideration. Claim 1 has been amended. The amendment is fully supported by the specification as filed and does not constitute new matter. By this amendment, Applicants have placed claims 1-6 and 35-37 in condition for allowance.

In the last Office Action, the Office rejected claim 1 under 35 U.S.C. § 112, second paragraph, as being indefinite. This claim has been amended to address the Office's rejection. The expression "derivative" has been replaced with "compound" to

LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000